IndieBio

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Synplexity is a biotechnology company located in New Castle, Delaware, specializing in mutational scanning and multiplexed gene synthesis through advanced artificial intelligence technology. The company operates a large-scale gene synthesis and proteomics discovery platform that utilizes microdroplets as microreactors. This innovative approach allows for the efficient creation of multiplex gene libraries, which have applications across various sectors, including therapeutics, biomanufacturing, agriculture, and climate systems. Synplexity aims to drive advancements in healthcare and other industries through its cutting-edge genetic technologies.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Avalo is a plant biology company that employs interpretable machine learning, genomic discovery, and evolutionary theory to expedite the development of new crops tailored for future agricultural needs. Utilizing AI-assisted plant breeding methods, Avalo creates non-GMO products that foster natural biodiversity. Its core technology, a discovery engine, can swiftly identify genetic bases of complex traits even in understudied crops, reducing time and cost significantly compared to traditional methods. This enables Avalo to forecast and enhance crop traits like drought tolerance and nutrient density, adapting agriculture to changing climates.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Reactosome is a biotechnology company that develops synthetic nuclei for gene therapy. Its core product, a synthetic nucleus, operates continuously within cells, mimicking the natural nucleus to affect multiple genes simultaneously. This approach aims to enhance the safety and longevity of gene expression, thereby enabling the development of treatments for complex diseases such as cancer and age-related disorders.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

TippingPoint Biosciences is developing therapeutics that target abnormal DNA packaging states in diseases such as cancer.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Wayfinder Biosciences is a biotechnology company focused on developing orally available small molecule drugs that modulate RNA targets linked to cancer and neurodegenerative diseases. The company uses a proprietary platform that combines high-throughput screening, computational modeling, and machine learning with unique datasets to discover RNA-targeting compounds with potency and selectivity for traditionally inaccessible targets. Its approach includes RNA biosensor technologies that render target molecules detectable, aiding discovery and evaluation. Founded in 2021 and based in Seattle, Wayfinder aims to accelerate development of therapies for undruggable targets by enabling rapid screening and optimization of RNA-targeting small molecules.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

SyntheX specializes in drug discovery using synthetic biology platforms. It identifies protein interaction modulators and enables functional protein degradation, focusing on unique mechanisms for cancer and rare disease treatments.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

AnimalBiome specializes in personalized pet nutrition, focusing on improving gut health for dogs and cats through microbiome science. The company offers microbiome tests to analyze pets' gut bacteria and provides tailored restorative supplements sourced from healthy animals to balance the microbiome.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

ArgenTAG is a biotechnology company specializing in genomic sequencing. It offers a proprietary technology designed to reduce the cost of long-read sequencing applications.

ArgenTAG is a biotechnology company specializing in genomic sequencing. It offers a proprietary technology designed to reduce the cost of long-read sequencing applications.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Indee Labs develops hardware and platform technologies for gene delivery to immune cells, with the aim of enabling the rapid development and scalable manufacture of gene-modified cell therapies, including CAR-T cells. The company focuses on non-viral delivery methods to introduce small molecules, nucleic acids, proteins, and gene-editing complexes into immune cells, supporting biopharmaceutical research and manufacturing while maintaining high cell viability and function. Its technology has progressed with collaboration from national facilities and through participation in biotech incubators and accelerators. Indee Labs maintains an international footprint, with an office in Sydney and lab space in Berkeley, reflecting its cross-regional development and manufacturing focus.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Avalo is a plant biology company that employs interpretable machine learning, genomic discovery, and evolutionary theory to expedite the development of new crops tailored for future agricultural needs. Utilizing AI-assisted plant breeding methods, Avalo creates non-GMO products that foster natural biodiversity. Its core technology, a discovery engine, can swiftly identify genetic bases of complex traits even in understudied crops, reducing time and cost significantly compared to traditional methods. This enables Avalo to forecast and enhance crop traits like drought tolerance and nutrient density, adapting agriculture to changing climates.

Wayfinder Biosciences is a biotechnology company focused on developing orally available small molecule drugs that modulate RNA targets linked to cancer and neurodegenerative diseases. The company uses a proprietary platform that combines high-throughput screening, computational modeling, and machine learning with unique datasets to discover RNA-targeting compounds with potency and selectivity for traditionally inaccessible targets. Its approach includes RNA biosensor technologies that render target molecules detectable, aiding discovery and evaluation. Founded in 2021 and based in Seattle, Wayfinder aims to accelerate development of therapies for undruggable targets by enabling rapid screening and optimization of RNA-targeting small molecules.

Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Microgenesis is a biotechnology company focused on fertility and pregnancy health monitoring. It has developed a platform that provides a non-invasive fertility test and personalized nutritional supplementation aimed at restoring women's fertility potential. The company's innovative diagnostic approach detects subclinical inflammation that negatively impacts ovarian function and implantation, specifically targeting women who have experienced challenges, including multiple failed IVF attempts. Operating out of a CLIA lab in Oakland, Microgenesis offers its solutions through OB-GYNs and direct-to-consumer channels. Additionally, the platform addresses imbalances in vaginal and intestinal microbiota linked to infertility and offers dual testing for immunological issues related to the endometrium, equipping patients with effective treatment options for complex reproductive health cases.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.

Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.

Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.

SyntheX specializes in drug discovery using synthetic biology platforms. It identifies protein interaction modulators and enables functional protein degradation, focusing on unique mechanisms for cancer and rare disease treatments.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.

Ivy Natal is a biotechnology company focused on addressing infertility through innovative reproductive solutions. The company has developed a skin biopsy technology that enables the creation of human egg cells from skin samples. This process activates the existing DNA within skin cells to transform them into healthy egg cells, offering a novel alternative to traditional in vitro methods for producing eggs and sperm. By circumventing the challenges associated with conventional reproductive techniques, Ivy Natal aims to provide couples, including those in same-sex relationships, with the opportunity to have genetically related children.

Circularis Biotechnologies, Inc. is a biotechnology company founded in 2014 and headquartered in Oakland, California. The company specializes in developing innovative methods to regulate gene expression, which enhances the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. In addition, it provides various services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its advanced technologies and services, Circularis aims to improve the efficiency and effectiveness of biotherapeutic production.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Pando Nutrition, Inc., founded in 2017 and headquartered in San Francisco, California, is an animal microbiome company focused on developing probiotics to promote livestock health and performance without relying on medically significant drugs. The company's primary goal is to address the antibiotic resistance crisis by engineering genetically modified probiotics that enhance feed efficiency, profitability, and methane emission control. Pando Nutrition offers Panbiotics, a platform designed to identify and manage methane emissions, thereby improving feed efficiency and livestock growth. Additionally, the company develops solutions for poultry pathogens like Coccidiosis and operates in the sustainable protein sector using yeast-based systems for animal feed.

Ravata Solutions develops a medical device platform for gene delivery used to create custom transgenic animal models and support production-scale embryo engineering. Founded in 2016 and based in Davis, California, the company targets pre-clinical research by enabling faster creation of transgenic organisms and improving embryo viability for disease modeling and fertility applications. The technology is designed to streamline model development for drug efficacy studies and medical genetics research, helping researchers accelerate timelines while enhancing the reliability of embryo production and genetic modification processes.

Founded in 2011, Dahlia Biosciences is a biotechnology company specializing in single-cell RNA analysis tools for research and diagnostic applications. It uses CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly in cells and tissues.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Serenity Bioworks is a biotechnology company focused on developing innovative antibody mimetics for targeted protein degradation. The company employs advanced display techniques alongside computational methods to optimize the discovery process of these therapeutics. Additionally, Serenity Bioworks is engaged in creating gene therapies aimed at addressing underserved areas in healthcare, such as hemophilia, inherited retinal diseases, and neurodegenerative conditions. Their goal is to enhance the long-term efficacy and safety profiles of gene therapy treatments, ultimately improving patient outcomes with safer and more durable solutions.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Founded in 2011, Dahlia Biosciences is a biotechnology company specializing in single-cell RNA analysis tools for research and diagnostic applications. It uses CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly in cells and tissues.

Osiris Bio

Serenity Bioworks is a biotechnology company focused on developing innovative antibody mimetics for targeted protein degradation. The company employs advanced display techniques alongside computational methods to optimize the discovery process of these therapeutics. Additionally, Serenity Bioworks is engaged in creating gene therapies aimed at addressing underserved areas in healthcare, such as hemophilia, inherited retinal diseases, and neurodegenerative conditions. Their goal is to enhance the long-term efficacy and safety profiles of gene therapy treatments, ultimately improving patient outcomes with safer and more durable solutions.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Founded in 2011, Dahlia Biosciences is a biotechnology company specializing in single-cell RNA analysis tools for research and diagnostic applications. It uses CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly in cells and tissues.

Onconetics Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies aimed at treating cancer and other genetic disorders. Established in 2016 and located in Mill Valley, California, Onconetics utilizes a unique therapeutic platform that incorporates a genetic switch to activate apoptotic inducers, selectively targeting tumor cells while preserving healthy tissue. The company is dedicated to advancing personalized medicine by integrating established gene therapy techniques with innovative research, striving to create effective treatments that reduce the invasiveness and side effects associated with traditional cancer therapies. Through its efforts, Onconetics aims to enhance patient outcomes and improve the overall quality of life for individuals affected by cancer and genetic conditions.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

Indee Labs develops hardware and platform technologies for gene delivery to immune cells, with the aim of enabling the rapid development and scalable manufacture of gene-modified cell therapies, including CAR-T cells. The company focuses on non-viral delivery methods to introduce small molecules, nucleic acids, proteins, and gene-editing complexes into immune cells, supporting biopharmaceutical research and manufacturing while maintaining high cell viability and function. Its technology has progressed with collaboration from national facilities and through participation in biotech incubators and accelerators. Indee Labs maintains an international footprint, with an office in Sydney and lab space in Berkeley, reflecting its cross-regional development and manufacturing focus.

Stelvio Therapeutics is a biopharmaceutical company focused on developing innovative therapies for incurable cancers and neurodegenerative diseases. The company utilizes a machine vision and learning platform to drive diseased stem cells to non-diseased states by identifying drugs that induce epigenetic changes. Its proprietary Microscopic Imaging of Epigenetic Landscapes (MIEL) technology facilitates the discovery of small molecules capable of differentiating or reversing cancerous cells into benign types, potentially offering curative outcomes. Founded in 2017 and headquartered in San Diego, California, Stelvio Therapeutics combines scientific creativity, clinical excellence, and professional management to advance novel drug therapies and precision medicine diagnostics, with a particular emphasis on personalized treatments for conditions such as glioblastoma.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Jungla Inc., established in 2016 and headquartered in South San Francisco, is a biotechnology company specializing in molecular function software for healthcare and pharmaceutical industries. It optimizes disease diagnosis by developing advanced functional genomics, computational biophysics, and computer science technologies. Jungla's platform proactively assesses genetic variant risks, providing quantitative insights to complement observational data. This enhances clinical genetic testing accuracy and delivers robust, scalable results. As of July 2019, Jungla operates as a subsidiary of Invitae Corporation.

Ravata Solutions develops a medical device platform for gene delivery used to create custom transgenic animal models and support production-scale embryo engineering. Founded in 2016 and based in Davis, California, the company targets pre-clinical research by enabling faster creation of transgenic organisms and improving embryo viability for disease modeling and fertility applications. The technology is designed to streamline model development for drug efficacy studies and medical genetics research, helping researchers accelerate timelines while enhancing the reliability of embryo production and genetic modification processes.

Ravata Solutions develops a medical device platform for gene delivery used to create custom transgenic animal models and support production-scale embryo engineering. Founded in 2016 and based in Davis, California, the company targets pre-clinical research by enabling faster creation of transgenic organisms and improving embryo viability for disease modeling and fertility applications. The technology is designed to streamline model development for drug efficacy studies and medical genetics research, helping researchers accelerate timelines while enhancing the reliability of embryo production and genetic modification processes.

AnimalBiome specializes in personalized pet nutrition, focusing on improving gut health for dogs and cats through microbiome science. The company offers microbiome tests to analyze pets' gut bacteria and provides tailored restorative supplements sourced from healthy animals to balance the microbiome.

SyntheX specializes in drug discovery using synthetic biology platforms. It identifies protein interaction modulators and enables functional protein degradation, focusing on unique mechanisms for cancer and rare disease treatments.

Jungla Inc., established in 2016 and headquartered in South San Francisco, is a biotechnology company specializing in molecular function software for healthcare and pharmaceutical industries. It optimizes disease diagnosis by developing advanced functional genomics, computational biophysics, and computer science technologies. Jungla's platform proactively assesses genetic variant risks, providing quantitative insights to complement observational data. This enhances clinical genetic testing accuracy and delivers robust, scalable results. As of July 2019, Jungla operates as a subsidiary of Invitae Corporation.

Genome Surveillance is a pioneering company focused on advancing DNA sequencing technologies to enhance speed and accuracy in genomic analysis. By utilizing innovative scaffold sequencing methods, Genome Surveillance addresses the challenges of high computational costs and inaccuracies associated with traditional sequencing approaches. The company's technology enables medical researchers to efficiently obtain reliable genomic information, facilitating genome reconstruction, structural variation discovery, molecular marker development, and agricultural research. By significantly reducing both the time and cost of sequencing, Genome Surveillance is positioned to meet the growing demand for precise genomic data in various scientific fields.

Amino Labs Inc. is a biotechnology company founded in 2015 and based in Canada. It focuses on making genetic engineering accessible to a broad audience, including individuals as young as eight years old. The company has developed an intuitive bioengineering mini-lab, a compact bioreactor that allows users to perform bacterial transformations and continuously grow cultures. This tabletop bioreactor facilitates hands-on learning about DNA, genes, and genetic engineering, empowering users to create a variety of biological products, such as fragrances, flavors, materials, and medicines. Through its innovative technology and user-friendly kits, Amino Labs aims to inspire a new generation of bioengineers and contribute to personalized manufacturing solutions addressing global challenges in fuel, food, and healthcare.

Genesis DNA is a company focused on revolutionizing the gene synthesis process, which involves converting digital sequences into physical DNA. Founded by a team of Stanford and MIT students, the company aims to address the limitations of current DNA construction methods, including high costs and lengthy turnaround times. Their proprietary technology enables rapid, affordable, and sequence-invariant gene synthesis, making it accessible for researchers to obtain any DNA sequence they require. Genesis DNA is driven by the belief that the next technological revolution will be rooted in biological advancements, positioning itself at the forefront of this emerging field.

At DtoR they have developed the PCR of gene expression—a disruptive technology that will revolutionize the tools used to “tune” protein production in any organism. In one step, and for any cell type, they can identify all of the switches regulating expression of the genome, as well as how active they are. They can also rapidly evolve or synthesize new switches to adapt to any application. Applications developed using their platform will lead to improved product yields in bioreactors, engineered specialty crops, optimized cancer therapeutics, and much more. The possibilities are limited only by their partners' imaginations.

Founded in 2012, Girihlet is a biotechnology company based in Oakland, California. It specializes in accurate profiling of T cell receptor repertoires using innovative sequencing technologies, aiming to advance understanding and management of immune system-related disorders.

Arcturus BioCloud, Inc. is a San Francisco-based company that operates a virtual bio-foundry designed for rapid prototyping of microorganisms through genetic engineering. It offers a user-friendly platform that enables scientists to code, create, share, and execute biotechnology experiments across the entire genetic engineering cycle. Users can upload their biological designs, which Arcturus BioCloud then builds and tests, thereby accelerating the development of innovative products. The company leverages partnerships with organizations like Synbiota and ZymoResearch to provide advanced technologies, with plans to expand its service offerings through additional collaborations. Arcturus BioCloud's mission is to democratize access to genetic engineering tools, enabling scientists globally to leverage state-of-the-art resources regardless of their location. The team behind the company, formed at Singularity University, encompasses a diverse range of expertise, positioning Arcturus BioCloud to capitalize on the growing biotechnology market driven by decreasing costs in synthesizing and sequencing technologies.

Ranomics is a biotechnology company that builds a comprehensive database of rare genetic variations and their associated disease risks to support interpretation of genetic data. Founded in 2015 and headquartered in San Francisco, with a location in Toronto, it provides tools to access and integrate genomic information, including RanomicsDB, a query interface with VCF support, and Ranomics API, a developer-friendly API that enables variant interpretation software to incorporate its data into existing pipelines. The company serves healthcare professionals and software developers, enabling cost-effective and rapid insights into genetic variation and health predictions to inform drug discovery, genomics screening, and personalized health decisions.